Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-08 16:00 |
to Present Research at the Single Cell Genomics 2025 Conference
|
English | 36.5 KB | ||
| 2025-08-28 16:00 |
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Confer…
|
English | 95.5 KB | ||
| 2025-08-28 16:00 |
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Confer…
|
English | 36.4 KB | ||
| 2025-08-06 16:30 |
Immediate Report of Meeting to be held on September 16, 2025
|
English | 255.1 KB | ||
| 2025-08-06 16:30 |
Immediate Report of Meeting to be held on September 16, 2025
|
English | 160.4 KB | ||
| 2025-08-06 16:00 |
Compugen Reports Second Quarter 2025 Results
|
English | 1.4 MB | ||
| 2025-08-06 16:00 |
Compugen Reports Second Quarter 2025 Results
|
English | 36.3 KB | ||
| 2025-07-28 16:00 |
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resi…
|
English | 93.6 KB | ||
| 2025-07-28 16:00 |
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resi…
|
English | 36.5 KB | ||
| 2025-07-23 16:00 |
to Release Second Quarter 2025 Results on Wednesday, August 6, 2025, conference…
|
English | 91.0 KB | ||
| 2025-07-23 16:00 |
to Release Second Quarter 2025 Results on Wednesday, August 6, 2025, conference…
|
English | 36.4 KB | ||
| 2025-07-21 16:00 |
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Plati…
|
English | 468.1 KB | ||
| 2025-07-21 16:00 |
Compugen Announces First Patient Dosed in COM701 Global Platform Trial in Plati…
|
English | 36.5 KB | ||
| 2025-06-12 15:59 |
Compugen to Present AI/ML Driven Predictive Computational Research at
Upcoming …
|
English | 92.7 KB | ||
| 2025-06-12 15:59 |
Compugen to Present AI/ML Driven Predictive Computational Research at
Upcoming …
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
